Stay informed and regularly check your security procedures to protect yourself, your business, and your customers. Photo via Getty Images

As news comes out every week about new technologies, from new crypto wallets to generative AI to self-driving taxis, it can get overwhelming for most of us to keep up or to understand the new intricacies of technology, and it can get easy to say, “The IT department has it covered.” Well, do they have it covered?

Far too often, companies fail to protect its data with the same muster as its financial security until it is too late. Just as a healthy business will regularly conduct audits of its accounting processes to detect potential fraud, ensure regulatory compliance, and locate areas of improvement for the organization, the same should be done for a business’s data security practices. Key components of any organization are its people and its information, and the IT department is in charge of protecting that information.

We as business people need to ensure that the company’s technology personnel are indeed securing one of the company’s most valuable assets: information.

Big picture: Your business needs to follow an audit process

  1. Confirm the scope of your data
  2. Conduct an internal review of all security practices
  3. Conduct a review of all vendor practices that have access to your data
  4. Confirm compliance with regulations and contractual obligations
  5. Prepare a report with detailed findings and recommendations to improve on year-over-year

Data: What do you have and what duties does it require?

Personal information, particularly when it belongs to customers, is the most frequently compromised type of data. Under laws like the newly passed Texas Data Privacy and Security Act (TDPSA), businesses can have additional obligations to keep this information protected. Personal information can include any information “that is linked or reasonably linkable to an identified or identifiable individual.”

Sensitive data also requires extra precaution, which means protecting (1) personal data that reveals racial or ethnic origin, religious beliefs, mental or physical health diagnosis, sexuality, or citizenship or immigration status; (2) genetic or biometric data that is processed for the purpose of uniquely identifying an individual; (3) personal data collected from a known child; or (4) precise geolocation data.

Other types of data to watch out for include the business’s intellectual property, anonymized customer data, employee personal information, and any other type of proprietary business data. Depending on the industry, the cost of a breach of any of these types of data could be incredibly high, particularly for healthcare and finance.

Ultimately, Texas businesses are required to maintain reasonable procedures to protect personal information, and there may be other laws implicated such as HIPAA, GLBA, CCPA/CPRA, BIPA, GDPR, PIPEDA, and many more, depending on where business is done, the industry implicated, and, in some cases, where customers are located.

"But I think the vendor is responsible."

Check your contracts, and check if the law requires you to have a duty to protect the compromised information, as many do. Involve your IT department in the review of technical compliance whenever you are sharing data with a third party. Further, it is important to make sure that however the Data Processing Addendum says the vendor is processing data is how they are actually processing data. To that point, if you are processing someone else’s data, your business also needs to be doing what it says it is doing, in contracts with third parties and in your Privacy Policy.

Software as a service arrangements, end user license agreements, and other internet and software-based services may require you to hand over data and not give you the opportunity to customize and shift risk. This is why it is important to thoroughly evaluate what technical protections are in place because the risk and duty may still fall on your business regarding the data of your customers and employees. Ask yourself (or your IT professionals) if the vendor actually needs the data they receive to provide services to you.

Key takeaway: Stay informed

Your business needs checks and balances in place with the IT department to ensure you know what they are (or are not) doing and what they are supposed to do. You need policies and procedures, and they need to regularly be tested.

Do you know where your data is stored, both internally and with third parties? Who controls it? How is it being processed, and is anything being shared? Are encryption procedures in place? Firewalls, Intrusion Protection Systems, and End-Point Detection and Response? Do you and your vendors have Incident Response Plans? Stay informed and regularly check your security procedures to protect yourself, your business, and your customers.

------

Courtney Gahm-Oldham is partner at Frost Brown Todd. Lauren Cole is associate at Frost Brown Todd.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.